Harvard Bioscience (HBIO) Operating Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Operating Expenses data on file, last reported at $13.4 million in Q1 2026.

• Quarterly Operating Expenses fell 78.31% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.1 million (down 52.68% YoY) and the FY2025 annual result came in at $98.5 million, up 61.52% from the prior year.
• Operating Expenses rose to $13.4 million in Q1 2026 per HBIO's latest filing, from $12.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $61.9 million in Q1 2025 and bottomed at $11.8 million in Q3 2025.
• The 5-year median for Operating Expenses is $15.7 million (2023), against an average of $17.9 million.
• The widest annual swing landed in 2025, when Operating Expenses soared 262.75%; it then slumped 78.31% in 2026.
• Tracing HBIO's Operating Expenses over 5 years: stood at $16.3 million in 2022, then fell by 1.52% to $16.0 million in 2023, then retreated by 12.73% to $14.0 million in 2024, then dropped by 10.99% to $12.5 million in 2025, then rose by 7.67% to $13.4 million in 2026.
• Per Business Quant, the three latest HBIO Operating Expenses figures stand at $13.4 million (Q1 2026), $12.5 million (Q4 2025), and $11.8 million (Q3 2025).

Peer Comparison